text stringlengths 9 93k |
|---|
Tony Blair is understood to have been told about the releases before Christmas. |
Mr Davies told Mr Clarke "that because of the culpable failure to protect the safety of the public, your position is untenable". |
Mr Clarke said 83 of the 288 released prisoners were now being considered for deportation, a further 53 had completed the process and 14 had been expelled. |
He said he would give details of efforts to track down the serious offenders who were released in error at a later date. |
In a statement, he told the Commons the failure of systems within the Home Office was "deeply regrettable" and his priority was now "to set that right". |
"It's clear that the increasing numbers of cases being referred for consideration led to the process falling down," he said. |
Mr Clarke told MPs he had said sorry for the oversight. "I do apologise. I have apologised, I continue to do so." |
But Mr Davis said although he had known the home secretary for 30 years and had "a broad degree of respect for him", Mr Clarke's statement revealed "a disturbing neglect for public safety at the heart of this government". |
"This is yet another example of your department's failure and incompetence. There is no excuse for you not knowing about this," he told Mr Clarke. |
And Sir Menzies pressed the prime minister at question time to explain why he had not asked for Mr Clarke to step down. |
Tory ex-Home Secretary Michael Howard also urged Mr Clarke to quit after his admission that "it was shocking failure on his part" that had led to the oversight. |
"If our traditional principles of ministerial responsibility mean anything at all, he should no longer be in his job," he told the BBC. |
Lord Ramsbotham, who was chief inspector of prisons between 1995 and 2001, said he had warned the Home Office that the numbers of foreign criminals in jail were increasing five years ago. |
He told BBC Radio 4's PM programme that he drew the government's attention to the problem in his last report in 2001 which was sent to ex-home secretary David Blunkett. |
Meanwhile, police have begun processing hundreds of names from the foreign prisoner scandal and have already returned results to the Home Office. |
The Association of Chief Police Officers (Acpo) said a team at its London HQ was running Police National Computer (PNC) checks on names being provided by the Home Office. |
The checks will reveal if police have current addresses for the missing 900 criminals, and whether any have committed further crimes since their botched releases. |
Earlier, Mr Blair said he did not agree with Conservative claims that Mr Clarke was unable to give the Home Office the leadership it needed. |
The prime minister has twice refused to accept the home secretary's offers to quit over foreign prisoner blunders. |
Number 10 said Mr Clarke had offered to resign on Tuesday when the scandal was uncovered. In interviews, Mr Clarke said he had offered to quit on an earlier occasion as well. |
Mr Blair said he regretted the oversights but added that new systems were now in place. |
He made the comments after Conservative leader David Cameron claimed Mr Clarke had presided over a "systemic failure" in the Home Office and had misled the public over the scale of the problem. |
"Isn't it clear that he cannot give the Home Office the leadership it so badly needs?" Mr Cameron asked, to Tory cheers. |
Mr Blair retorted: "It won't surprise you to know I don't agree with that." |
‘I feel like I’m always in a battle with my feet,” says Lauren Lovette, with a sigh. One of New York City Ballet’s principal ballerinas, Lovette has beautifully arched, supple feet, and often, they’re killing her. |
After years of sprains and other injuries, she underwent surgery to correct a bone anomaly, but even with physical therapy, daily ankle exercises, ice baths and ointments, the 25-year-old still hasn’t made peace with her feet. |
Lovette shares this struggle with many dancers, whose feet take sustained abuse, and in the worst kind of footwear (or none at all). While they may run, jump, squat, leap and pivot like any NBA star, dancers do it without shock absorption, arch support or any foot-comfort features whatsoever. Athletes get to wear shoes... |
I had my own flirtation with pointe shoes as a ballet student in my youth, and I’ll never forget my alarm as I slid my feet into my first pair. Little bones I didn’t know I had were suddenly squeezed in a death grip. Pointe shoes may look dainty, but there’s an Elizabethan-corset quality to them, reflecting their serio... |
In anticipation of New York City Ballet’s engagement at the Kennedy Center from June 6 to 11, I’ve been thinking about the incomparable strength of the ballerina, especially when it comes to her toes and what it takes to dance on them. |
Dancing on the toes revolutionized ballet in 1832, when Italian ballerina Marie Taglioni caused a sensation in “La Sylphide.” In the title role of a highland fairy, she seemed to briefly trod the air, rising on the tips of her satin slippers, which she had reinforced with darning. As her trick caught on, and choreograp... |
Pointe shoes are still made that way today, with cotton-lined satin, a rigid insole — or shank — and a cupped portion around the toes that is hardened with glue, canvas and paper. Because the shoe and the foot must work together as one, it’s up to each dancer to customize her pointe shoes. Even the most exalted balleri... |
Unlike ballplayers, ballerinas in the major companies have to sew and break in new shoes almost every day. A pointe shoe’s life is measured in hours of wear. At a cost of around $100 (usually paid by the company), a pair may last a pro for a full day of class and rehearsal, but if she’s starring in “Swan Lake,” or danc... |
Claire Kretzschmar, a member of New York City Ballet’s corps de ballet, lays her new shoes on the ground, sole up, and stomps on them. After that, she pours quick-drying Jet Glue (developed for model airplanes, now a pointe shoe standard) on the tips for extra hardening. To protect her toes, she wraps them in a brown p... |
Pointe shoes are an extension of their bodies, an essential tool of expression, and ballerinas get attached not only to their brand — most popular among professionals are Freed (made in England) or Bloch (from Australia) — but also to the individual maker who handcrafts the shoe. It can be traumatic to change makers. J... |
“I wrote him a letter,” Kent says, “and sent a photograph of myself in ‘Giselle’ praying, looking very pleading, saying would he consider just making a limited amount of shoes for me a year.” It didn’t work. She eventually asked Bloch to copy an old shoe. While dancing as a guest with the Australian Ballet, Kent went t... |
In such a competitive profession, rest doesn’t come easily. Ballet dancers have a very high pain threshold, says Washington podiatrist Stephen Pribut. It may be a combination of pain resistance and paranoia that gives them the ability — unwise as it may be — to dance through injury. Kretzschmar has been dogged by stres... |
After that last performance before the operation, “walking out of the theater was scary,” Lovette says. “What if I’m forgotten about? That’s always a dancer’s fear.” That was two years ago. After months of recovery, she returned to the stage, newly promoted to the top rank, her foot problems behind her. That is, until ... |
How a ballerina treats her feet off-duty is important, Pribut says. And it’s true for any of us. Our footwear is an essential tool no matter what we do. Some shoes, worn too often, can cause more strain than pointe shoes, the doctor adds. Common culprits are flip-flops, high heels and what few dancers would ever wear o... |
Dr. Jane A. Goodall addressed students and faculty in a spiritual service entitled “A Service of Hope” yesterday, in her final appearance as an A.D. White Professor-at-Large. Goodall spoke to a packed Sage Chapel on many life lessons she has acquired and, more specifically, during her four decades as a world-renown sci... |
The service, sponsored by the A.D. White Office and the Cornell United Religious Work, also included musical selections performed by the Sage Chapel Choir and the readings of passages from Goodall’s Reason for Hope: A Spiritual Journey. |
Goodall, who amassed worldwide notoriety for her studies with chimpanzees, has received numerous international awards throughout her career including the National Geographic Society’s Hubbard Medal. She has also received such honors as Commander of the Order of the British Empire by H.M. Queen Elizabeth II. |
On Tuesday, she was named a messenger of peace by the United Nations, an honor bestowed upon only ten recipients around the world. |
Introducing Goodall, Rev. Kenneth I. Clarke, director of Cornell United Religious Work, called her a “world citizen” in reference to her numerous contributions to science and her worldwide humanitarian gestures. |
Goodall began the address recounting her interest in Africa and its wildlife. While she was fascinated by jungle life, she had no finances to pursue a college education when she finished high school and worked menial jobs to save enough money to study in Africa. She also mentioned the difficulties she faced early on as... |
However, Goodall underscored the crucial role her mother played in encouraging her early fascination with wildlife and the pursuit of science. “She nurtured these dreams,” Goodall said. |
Goodall used personal anecdotes to demonstrate the personality and developed character of the chimpanzees with whom she worked in Africa. |
She stressed the need to understand humanity’s role in the natural world. |
“[We need to] make people understand our relationship with the animal kingdom,” she said. |
According to Goodall, humans are distinguished from the rest of the animal kingdom only by the creation of sophisticated languages, and with this ability comes worldwide responsibility. |
“This ability we have to communicate in such a way … puts us in a position of stewardship over the planet,” she said. |
Goodall also expounded on what she felt are the most pressing global problems. She expressed her concerns with natural issues such as endangered species, pollution and deforestation and with humanitarian issues such as worldwide hunger, violence, AIDS and other epidemics. |
“It’s a very frightening world,” she said in reference to all of these challenges. |
However, she also emphasized four reasons that she remains hopeful for the future: humanity’s ability to think, the resilience of nature and its capacity to heal itself, the human spirit of energy and finally the promise of youth in efforts such as Roots and Shoots, a worldwide humanitarian program for youth that she s... |
Goodall, who was in New York City during the events of Sept. 11, used her podium to reflect on the catastrophe and its aftermath. |
“We witnessed the very worst of what we were capable of doing … but at the same time, some of the best,” said Goodall in reference to the events of Sept. 11 and the heroic efforts of rescue workers and concerned people all over the world. “I’d like to think that those innocent people did not die in vain. |
Goodall’s speech was met with praise. The service was followed by a book signing in the Willard Straight Memorial Room, where a long line of attendees gathered to meet the renown scientist. |
Goodall was also met by much appreciation and support by the Cornell faction of Roots and Shoots. |
In an exclusive "Globes" interview, the former Teva CEO speaks openly for the first time about the reasons for Teva's plight. |
When Jeremy Levin left his position as CEO of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) four years ago, some said it proved that a non-Israeli CEO could not succeed at Israel's largest and leading company. Levin did whatever he could to connect with Israel: he moved his home to Israel, learned Hebrew... |
When Levin was appointed to manage Teva, the company's share price soared. As time went on, however, and Levin presented a relatively modest strategic plan based on small innovative acquisitions, improving existing products, and large-scale layoffs, rather than the large and rousing acquisitions to which Teva's investo... |
Today, many people in Teva miss Levin and his feasible and low-debt strategic plan; the cutbacks he wanted to make in the company, which now appear essential; the emphasis he planned to put on the innovative market, rather than the generics market; his understanding of the international pharma industry; and most of all... |
In an exclusive "Globes" interview, he says, "To this day, I still don't understand this episode (in which he was fired, G.W.), but I don't look back. A large proportion of the board of directors that made that decision is no longer at the company." |
"Globes": Is there any chance that you will ever return to Teva? |
Levin: "Absolutely not. I love Israel, and I gained many friends at Teva, but it's not a company I regard as part of me, despite my great appreciation for (chairperson) Sol Barer and (incoming CEO) Kare Schultz." |
Levin has consistently refused to express his opinion of what happened at Teva after he left. Now that the picture has been revealed in all its gloominess, however, he has decided to change this, and to present his analysis of the events that have occurred, and which have brought Teva to its current plight. He sets out... |
"The causes of the current decline are mostly known: the attack on Mylan, the acquisition of Actavis (at the time, when the acquisition was first made, and few dared to criticize it, Levin said cynically that the acquisition was 'excellent' for Allergan, the selling company, G.W.), the acquisition of Rimsa, and the fai... |
"During the period of Eli Hurvitz, Israel Makov, and Shlomo Yanai, Teva relied primarily on one business plan that included the launching of generic products based on Paragraph IV (which allowed a long period of exclusivity for the first concern reaching the generics market), and later also on Copaxone. In 2011, when I... |
"The drop in prices in the generics market was also expected. In a commodities market like the generics market, in which there is a lot of competition over similar products, prices always eventually fall. When I got to Teva, everything was already clear - the expected consolidation of drug purchasers and the growing co... |
"As Teva's CEO, I devised a comprehensive plan designed to cope with all of these things. I don't know whether it was implemented. I do know that with the acquisition of Actavis, they acquired many plants, and that immediately made them less efficient. It's very surprising, because it was the company's Israeli managers... |
Should your plan for generics still be applied? |
"I'm not sure whether it can still be applied." |
Teva was always called "the world's largest generics company," and it seemed like this phrase was sometimes substituted for a vision for the company. Might this positioning have been too prominent in Vigodman's consciousness when he decided to acquire Actavis? |
"I really don't know what Vigodman thought. Bigger, of course, is not always better. Eli Hurvitz's vision was a profitable and international company." |
Do you support splitting the company into two: an innovative company and a generics company? |
"That's an interesting idea, but since they're so deep into generics right now, they have to do their best in this sector." |
What about the innovative sector? |
"Success in the innovative sector is based on acquisition of a lot of small companies, each of which usually has a single product. The innovative division, which was managed by Dr. Michael Hayden (Levin's appointment, G.W.), acquired several good products. The product for migraines looks especially successful. No compa... |
"The markets at which the innovative products that Teva is about to launch are aimed, especially the migraine market, are very competitive. Fortunately, it appears that these products will be marketed by the Copaxone marketing team, which is one of Teva's treasures. They are the company's unacknowledged heroes." |
One of the interesting innovations in Levin's plan was the focus on NTEs - products based on known molecules, but with some improvement that differentiates the product from others. Since Levin left, no one has talked about NTEs, but it is now clear that the plan was not abandoned. A source informed about Teva told "Glo... |
"The Austedo product for movement disorders, one of Teva's leading products, is actually an NTE, because it's based on a new release method for the already known molecule. This product was acquired from outside, but the company's original NTEs were also developed - for example, an opiate-based pain reliever with protec... |
"Today, when Teva lacks resources, it can no longer develop these products, because they require more investment than a generic product, and their marketing is also not profitable from the very beginning, and Teva has no time. When Actavis was acquired, the official statement was that it would generate the revenue that... |
Teva has a new CEO now. Like Levin, he is not an Israeli, and comes from the innovative sector. The two men know each other well, because when Levin was a director in Lundbeck when Schultz was CEO of the company. |
"Together with Sol Barer, however, who has a good understanding of the field and is an excellent manager, they can rebuild the company. Initial measures have already been taken with the layoffs plan and the new organizational structure, but there's a long way ahead. At the end, it will be a different company." |
"Kare is known as a very successful manager, above all in stabilizing companies in cash flow and financially. Certainly, the first thing he has to contend with is cash flow and debt. Once he stabilizes this and makes sure that he's got a profitable business that is based on neither Copaxone nor Paragraph IV, he can thi... |
"I wish Teva a lot of success, because it's an important company for Israel. It's an iconic company that inspires a lot of people. It's still a great example of how to build a company in Israel." |
"The next thing is neurology" |
Levin was pushed out of Teva in 2013 by then chairperson Frost, with the support of the board of directors. After he left, the company was without a CEO for several months, until the selection committee eventually chose Erez Vigodman as the next CEO, and the rest is history. |
Levin has recovered from the crisis, but anyone who expected him to become CEO of a company on the same scale was disabused. Fairly soon after he left, he became a director in companies like Biocon, an Indian company that, like Teva, expanded from the generics field into directions of innovative drugs and improved gene... |
Levin, who is also CEO of Ovid and holds shares in the company, says, "When I left Teva, I was offered a position as manager of a bigger company, but they wouldn't allow me to develop this field. I therefore decided to build a company in this field by myself. Ovid is one of the first companies in the world built with t... |
Not everyone remembers it, but Levin came to Teva as head of strategy and acquisitions at Bristol-Mayers Squib (BMS), where he developed the company's immunooncology business, which revolutionized cancer treatment. BMS brought the world's first immunooncological solid-cancer drug, Yervoy, for the treatment of melanoma,... |
"Already in 2006-2007, I was convinced that the next thing was neurology," he says. "When I got to Teva, I wanted to focus on this area. That's why I selected Michael Hayden (who left the company this week) as chief scientist. My confidence in the field only grew over the years. I saw, and I still see, that the entire ... |
"We're beginning from a very great opportunity of 100 hereditary generic diseases leading to various types of autism, epilepsy, and developmental disability. We're coming to the neuro-developmental field with a new understanding of a specific brain mechanism called tonic inhibition, which affects the choice between a s... |
"We began our trials with a disease called Angelman syndrome," Levin explains. This syndrome features movement and cognitive disturbances. "We're now in Phase II trials on adults, which will probably finish in 2018, and we're assessing the product for teenagers. Our goal is to get to babies, because the earliest treatm... |
Angelman syndrome sufferers number several thousand children and adults in the US. In the case of the second syndrome the company is expected to attack, however, Fragile X syndrome, there are tens of thousands of patients. Trials of a treatment for this disease will begin soon. A drug for treatment of genetic epilepsy ... |
"We started an initial trial in June, and we'll get results in 2018. Our partner for development of the product is Takeda Pharmaceutical Company, which comes from Japan. In a very unique agreement, Takeda, which discovered the drug, transferred its development to us. We'll be responsible for both development and market... |
As of now, you are developing these drugs for genetic developmental diseases. Is it possible that they will be suitable for common diseases at a more advanced age, such as Alzheimer's disease and Parkinson's disease? |
"We think that it's a definite possibility." |
Ovid's current market cap on Nasdaq is $263 million. The company's share price soared immediately after its IPO, but then fell to 29% below the price in the IPO, without any negative announcements. |
"Most Teva Israel layoffs will be at head office" |
How did it feel to raise capital on Nasdaq as a young company, not a big one? |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.